Colorectal cancers differ in respect of PARP-1 protein expression

Violetta Sulzyc-Bielicka; Pawel Domagala; Jolanta Hybiak; Anna Majewicz-Broda; Krzysztof Safranow; Wenancjusz Domagala

eISSN: 2084-9869
ISSN: 1233-9687

Polish Journal of Pathology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2012
vol. 63

Send email

Copy url:

abstract:

Colorectal cancers differ in respect of PARP-1 protein expression

Violetta Sulzyc-Bielicka

,

Pawel Domagala

,

Jolanta Hybiak

,

Anna Majewicz-Broda

,

Krzysztof Safranow

,

Wenancjusz Domagala

POL J PATHOL 2012; 2: 87-92

Online publish date: 2012/08/03

View full text Get citation

Recent findings raise the possibility of PARP inhibitor therapy in colorectal cancers (CRCs). However, the extent of PARP-1 protein expression in clinical specimens of CRC is not known. Using immunohistochemistry we assessed PARP-1 protein expression in tissue microarrays of 151 CRCs and its association with the patient’s age, sex, Astler-Coller stage, grade and site of the tumor. High PARP nuclear immunoreactivity was found in 68.2% (103/151) of all cases. In turn, 31.8% (48/151) of tumors showed low PARP expression, including 9 (6%) PARP-1 negative CRCs. There was a significant association of PARP-1 expression with the site of CRC and Astler-Coller stage. A high PARP expression was noted in 79.1% of colon vs. 53.9% of rectal tumors (p = 0.001). The mean PARP-1 score was 1.27 times higher in colon vs. rectal cancers (p = 0.009) and it was higher in stage B2 vs. stage C of CRCs

(p = 0.018). In conclusion, the level of PARP-1 protein nuclear expression is associated with the tumor site and heterogeneous across clinical specimens of CRC, with the majority of CRCs expressing a high level but minority – low or no PARP-1 expression. These findings may have a clinical significance because the assessment of PARP-1 expression in tumor samples may improve selection of patients with CRC for PARP inhibitor therapy.

keywords:

Colorectal cancers differ in respect of PARP-1 protein expression

Violetta Sulzyc-Bielicka , Pawel Domagala , Jolanta Hybiak , Anna Majewicz-Broda , Krzysztof Safranow , Wenancjusz Domagala

PARP-1, colorectal cancer, PARP inhibitor, colorectal cancer therapy

Violetta Sulzyc-Bielicka

,

Pawel Domagala

,

Jolanta Hybiak

,

Anna Majewicz-Broda

,

Krzysztof Safranow

,

Wenancjusz Domagala